ABT240712C107000
- 0.04
- -0.04-50.00%
Abbott Laboratories Newsroom
Financial Stocks Deliver Profits in Q2 Amid Rebound in Investments - Earnings Scorecard
Abbott Laboratories To Go Ex-Dividend On July 15th, 2024 With 0.55 USD Dividend Per Share
July 11th (Eastern Time) - $Abbott Laboratories(ABT.US)$ is trading ex-dividend on July 15th, 2024.Shareholders of record on July 15th, 2024 will receive 0.55 USD dividend per share on August 15th, 20
Here's How Abbott (ABT) Is Placed Ahead of Q2 Earnings Release
The price of West Texas Intermediate (WTI) crude oil is trading at more than the $80 per barrel mark and is likely to remain strong this year.
Wall Street Bulls Look Optimistic About Abbott (ABT): Should You Buy?
TD Cowen Maintains Abbott Laboratories(ABT.US) With Buy Rating, Maintains Target Price $130
TD Cowen analyst Josh Jennings maintains $Abbott Laboratories(ABT.US)$ with a buy rating, and maintains the target price at $130.According to TipRanks data, the analyst has a success rate of 52.3%
Buy Rating Affirmed for Abbott Laboratories Amidst Strong Growth and Manageable Risks
Looking Into Abbott Laboratories's Recent Short Interest
Abbott Laboratories's (NYSE:ABT) short percent of float has fallen 20.24% since its last report. The company recently reported that it has 11.62 million shares sold short, which is 0.67% of all
Goldman Sachs Adjusts Price Target on Abbott Laboratories to $118 From $121
Abbott Laboratories (ABT) has an average rating of outperform and price targets ranging from $104 to $143, according to analysts by Capital IQ.Price: 101.72, Change: +0.08, Percent Change: +0.08
Susudu Zhilian's IPO is terminated by the Shenzhen Stock Exchange. The company is a comprehensive full-service e-commerce operation service provider.
On July 9th, Peking Shuju Zhilian Technology Co., Ltd. (referred to as Shuju Zhilian) terminated its IPO on the Shenzhen Stock Exchange Growth Board.
Wells Fargo Maintains Abbott Laboratories(ABT.US) With Buy Rating, Maintains Target Price $133
Wells Fargo analyst Larry Biegelsen maintains $Abbott Laboratories(ABT.US)$ with a buy rating, and maintains the target price at $133.According to TipRanks data, the analyst has a success rate of 58.3
DexCom (DXCM), Abbott to Launch First FDA Cleared OTC CGMs
Is Abbott Laboratories (ABT) a Good Dividend Growth Stock to Buy and Hold According to Hedge Funds?
TorHoerman Law Advocates for Infants in Pivotal Missouri NEC Trial Against Formula Manufacturers
ST. LOUIS, July 3, 2024 /PRNewswire/ -- TorHoerman Law is set to begin trial on July 8, 2024, in Missouri state court. The case will focus on allegations that cow milk-based baby formula is linked to
Abbott Labs Is Maintained at Outperform by Evercore ISI Group
Abbott Labs Is Maintained at Outperform by Evercore ISI Group
7 Analysts Have This To Say About Abbott Laboratories
Analysts' ratings for Abbott Laboratories (NYSE:ABT) over the last quarter vary from bullish to bearish, as provided by 7 analysts.The following table provides a quick overview of their recent ratings
Abbott Laboratories Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/02/2024 16.35% Evercore ISI Group $125 → $120 Maintains Outperform 06/04/2024 21.19% RBC Capital $125 →
Evercore Maintains Abbott Laboratories(ABT.US) With Buy Rating, Maintains Target Price $120
Evercore analyst Vijay Kumar maintains $Abbott Laboratories(ABT.US)$ with a buy rating, and maintains the target price at $120.According to TipRanks data, the analyst has a success rate of 47.4% and a
Evercore ISI Adjusts Price Target on Abbott Laboratories to $120 From $125, Maintains Outperform Rating
Abbott Laboratories (ABT) has an average rating of outperform and price targets ranging from $104 to $143, according to analysts polled by Capital IQ.
Barclays Maintains Abbott Laboratories(ABT.US) With Buy Rating, Maintains Target Price $140
Barclays analyst Matt Miksic maintains $Abbott Laboratories(ABT.US)$ with a buy rating, and maintains the target price at $140.According to TipRanks data, the analyst has a success rate of 59.5% and a
Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT) and Springworks Therapeutics (SWTX)